Cargando…

Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta

BACKGROUND: A relatively large proportion of relapsing-remitting multiple sclerosis (RRMS) patients do not respond to interferon-beta (IFNb) treatment. In previous studies with peripheral blood mononuclear cells (PBMC), we identified a subgroup of IFNb non-responders that was characterized by a base...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bustamante, Marta F., Nurtdinov, Ramil N., Río, Jordi, Montalban, Xavier, Comabella, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630153/ https://www.ncbi.nlm.nih.gov/pubmed/23637780 http://dx.doi.org/10.1371/journal.pone.0060994

Ejemplares similares

Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple Sclerosis
por: Malhotra, Sunny, et al.
Publicado: (2011)

Treatment with MOG-DNA vaccines induces CD4(+)CD25(+)FoxP3(+) regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis
por: Fissolo, Nicolás, et al.
Publicado: (2012)

Serum Levels of CXCL13 Are Associated With Teriflunomide Response in Patients With Multiple Sclerosis
por: Fissolo, Nicolás, et al.
Publicado: (2022)

Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure
por: Malhotra, Sunny, et al.
Publicado: (2023)

Circulating EZH2-positive T cells are decreased in multiple sclerosis patients
por: Malhotra, Sunny, et al.
Publicado: (2018)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Identification of a Novel Risk Locus for Multiple Sclerosis at 13q31.3 by a Pooled Genome-Wide Scan of 500,000 Single Nucleotide Polymorphisms
por: Comabella, Manuel, et al.
Publicado: (2008)

Metabolomic signatures associated with disease severity in multiple sclerosis
por: Villoslada, Pablo, et al.
Publicado: (2017)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
por: Malekzadeh, Masoud Mohammad, et al.
Publicado: (2020)

Baseline MxA mRNA Expression Predicts Interferon Beta Response in Multiple Sclerosis Patients
por: Matas, Elisabet, et al.
Publicado: (2014)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

Lesion topographies in multiple sclerosis diagnosis: A reappraisal
por: Arrambide, Georgina, et al.
Publicado: (2017)

Cytokine profiles show heterogeneity of interferon-β response in multiple sclerosis patients
por: Hegen, Harald, et al.
Publicado: (2016)

Pharmacogenomics of Interferon-ß Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients
por: van Baarsen, Lisa G. M., et al.
Publicado: (2008)

Interferon Beta and Vitamin D Synergize to Induce Immunoregulatory Receptors on Peripheral Blood Monocytes of Multiple Sclerosis Patients
por: Waschbisch, Anne, et al.
Publicado: (2014)

Predictive value of early brain atrophy on response in patients treated with interferon β
por: Pérez-Miralles, Francisco Carlos, et al.
Publicado: (2015)

Chitinases and chitinase-like proteins as biomarkers in neurologic disorders
por: Pinteac, Rucsanda, et al.
Publicado: (2020)

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results
por: Link, Jenny, et al.
Publicado: (2017)

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis
por: Penner, Iris-Katharina, et al.
Publicado: (2012)

Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis
por: Malhotra, Sunny, et al.
Publicado: (2015)

Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis
por: Croze, E, et al.
Publicado: (2013)

‘Beta-interferons’ and ‘oligoclonal bands’ in multiple sclerosis in India
por: Hassan, K. M.
Publicado: (2011)

Acceptance of the Extracare Program by Beta Interferon-Treated Patients With Multiple Sclerosis: Results of the Explore Study
por: Freidel, Matthias, et al.
Publicado: (2015)

Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab
por: Allinovi, Marco, et al.
Publicado: (2017)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Kolind, Shannon, et al.
Publicado: (2022)

Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-β
por: Bustamante, Marta F., et al.
Publicado: (2015)

Interferon beta treatment is a potent and targeted epigenetic modifier in multiple sclerosis
por: Xavier, Alexandre, et al.
Publicado: (2023)

Response to Interferon-Beta Treatment in Afro-Caribbeans with Multiple Sclerosis
por: Jeannin, S., et al.
Publicado: (2011)

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials
por: Vidal-Jordana, Angela, et al.
Publicado: (2021)

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
por: Lim, Ee Tuan, et al.
Publicado: (2004)

MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients
por: Serana, Federico, et al.
Publicado: (2014)

An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a
por: Yamazaki, Yuichi, et al.
Publicado: (2017)

Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis
por: Freedman, Mark S., et al.
Publicado: (2021)

Interferon–β Induces Hepatocyte Growth Factor in Monocytes of Multiple Sclerosis Patients
por: Molnarfi, Nicolas, et al.
Publicado: (2012)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

Multiple sclerosis: Immunopathological heterogeneity and its implications
por: Engelhardt, Britta, et al.
Publicado: (2022)

Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study
por: Zettl, Uwe K, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_b9uevj6748vsj19r9v0837si69